Study of Dextromethorphan in OCD and Related Disorders

• Status: Not yet recruiting
• Trial end date: 2025-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Collaborator: Avy L. & Roberta L. Miller Foundation
• Treatments: Dextromethorphan; Fluoxetine

Criteria

Inclusion Criteria:

• Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)

• Living within California

• Capacity to provide informed consent

Exclusion Criteria:

• Current bipolar disorder or psychotic disorder

• Active moderate or severe substance use disorder, lifetime severe substance use disorder

• Pregnant or nursing women

• Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start

• Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start